ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stock options have an exercise price equal to the closing price of ORIC's common stock on the Grant Date. Twenty-five percent (25%) of the shares subject to the stock options will vest on the one (1) year anniversary of the Grant Date, with one thirty-sixth (1/36th) of the remaining shares vesting each one-month period thereafter. One-third (1/3rd) of the restricted stock units will vest on each of the first three anniversaries of the Grant Date. The inducement grants are subject to the terms and conditions of the applicable stock option and restricted stock unit agreements and the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan.
The inducement grants were approved by ORIC's Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the vesting of the inducement grants; target indications for ORIC's product candidates; the potential advantages of ORIC's product candidates; and plans underlying ORIC's clinical trials and development. Words such as 'believes,' 'anticipates,' 'plans,' 'expects,' 'intends,' 'will,' 'goal,' 'potential' and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC's ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC's plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC's product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC's operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC's license and collaboration agreements; the potential market for our product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC's ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC's reliance on third parties, including contract manufacturers and contract research organizations; ORIC's ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in ORIC's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the 'SEC') on May 5, 2025, and ORIC's future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Contact:Dominic Piscitelli, Chief Financial Officerdominic.piscitelli@oricpharma.com info@oricpharma.comInicia sesión para acceder a tu cartera de valores
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Cuomo to run as third-party candidate in NYC after loss to Mamdani
Former New York Gov. Andrew Cuomo (D) formally announced he is running as an independent in New York City's mayoral race in November after losing to Democratic nominee Zohran Mamdani in the party's primary. 'Only 13 percent of New Yorkers voted in the June primary. The general election is in November and I am in it to win. My opponent Mr. Mamdani offers slick slogans, but no real solutions,' Cuomo said in a campaign video posted to the social platform X on Monday. 'We need a city with lower rent, safer streets, where buying your first home is once again possible, where childcare won't bankrupt you. That's the New York City we know,' he continued. 'You deserve a mayor with the experience and ideas to make it happen again and the guts to take on anybody who stands in the way,' he said. A source close to Cuomo's campaign told The Hill's partners at NewsNation earlier Monday that Cuomo will ask all candidates except for Mamdani to pledge that any candidate who is not in the lead by mid-September will drop out of the race, himself included. Cuomo joins Mamdani, Mayor Eric Adams, who is also running as an independent, and Republican Curtis Sliwa in the general election race. Mamdani defeated Cuomo by about 12 points, 56 percent to 44 percent, in the third round of ranked choice voting in the primary. Mamdani's critics fear that a crowded general election could result in his opponents splitting the vote, easily handing Mamdani a victory. Adams said last month that Cuomo asked him to drop his independent bid for reelection, but a number of prominent figures have called on Cuomo to drop out of the race to unify around Adams, including hedge fund billionaire Bill Ackman, who had donated a significant amount of money to Cuomo's campaign in the primary. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
25 minutes ago
- Yahoo
Conagra Brands, Inc. (CAG) Had To 'Eat' The Tariff, Says Jim Cramer
We recently published . Conagra Brands, Inc. (NYSE:CAG) is one of the stocks Jim Cramer recently discussed. Conagra Brands, Inc. (NYSE:CAG) is a food products company, which, like its peers, has struggled on the stock market in 2025. The firm's shares have lost close to 30% in 2025 and are down by 10% over the past month. Conagra Brands, Inc. (NYSE:CAG)'s latest share price dip came in July after the stock fell by 4.4% after the firm's fiscal fourth quarter earnings report. The result saw it miss analyst EPS and revenue estimates of $0.58 and $2.83 billion by posting $0.56 and $2.78 billion. Conagra Brands, Inc. (NYSE:CAG) also missed analyst fiscal 2026 guidance by a wide margin as its midpoint EPS of $1.775 was nowhere close to the $2.18 analysts had penciled in. The miss was due to tariffs, and here's what Cramer said: 'Overlooked was the Conagra, which does not have great brands historically had to eat the tariff on tin cans and their inflation rate's gonna be 7% and that's why that stock got so many different price target cuts. A worker assembling a meal in a food production facility. Previously, Cramer mentioned that Conagra Brands, Inc. (NYSE:CAG) was removing dyes from its products: 'Conagra, and . . . Nestle, are all taking the dyes out. The synthetic dyes.' While we acknowledge the potential of CAG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
36 minutes ago
- Yahoo
All-Time Highs for Stocks: These 2 ETFs Still Look Undervalued
The persistent high-interest rate environment has prevented the Vanguard Real Estate ETF from rallying. International stocks have outperformed but still look attractively valued. There's an excellent high-dividend Vanguard ETF that could still be a smart buy. 10 stocks we like better than Vanguard Real Estate ETF › The S&P 500 recently reached a new all-time high, and many stocks are at or near their own 52-week highs. But there are two important things for ETF investors to know. First, not all ETFs are near all-time highs. In fact, some are still down by 10% or more from their recent peaks. Second, just because a certain ETF is at a new high doesn't always mean that it's expensive. And with these principles in mind, here are three Vanguard ETFs that look incredibly attractive even with many stocks reaching new highs. The real estate sector hasn't exactly been a strong performer in recent years. In fact, the Vanguard Real Estate ETF (NYSEMKT: VNQ) has produced a 73% total return over the past decade, compared with 264% for the S&P 500. However, it's important to point out that the last decade has seen two Federal Reserve rate hike cycles and a pandemic that essentially rendered commercial real estate inoperable for a period of time. The actual businesses of real estate investment trusts (REITs) have generally performed well -- it's just a highly rate-sensitive business. Not only do higher rates cause borrowing costs to rise, but commercial property values have an inverse relationship with the prevailing risk-free interest rates, like Treasuries. While there's no way to know when the Fed will start cutting rates again, most experts agree that the general direction of interest rates over the next couple of years is likely to be downward. This should provide the tailwind the Vanguard Real Estate ETF needs to start producing outsized returns. The Vanguard International High Dividend Yield ETF (NASDAQ: VYMI) just hit a new all-time high on the day this article was written. But that doesn't necessarily mean it's expensive. In fact, compared with U.S. high dividend stocks, it looks extremely cheap. This ETF owns a portfolio of about 1,550 companies based outside of the United States that have above-average dividend yields. But these aren't just companies you haven't heard of -- household names like Toyota and Nestle are among the top holdings, and there are several other major components that you're probably familiar with. As of this writing, the ETF has a 4.1% dividend yield, but of course it might be slightly different by the time you're reading. Here's the key point. The average stock in the Vanguard International High Dividend Yield ETF's index has grown earnings at a 13.7% annual rate over the past five years and trades for just 12 times earnings. That's a remarkably low valuation, especially considering that the stocks in the U.S. counterpart Vanguard High Dividend Yield ETF (NYSEMKT: VYM) have an average P/E of more than 19 and have grown earnings slower. Of course, there are additional risks when investing in international stocks, such as foreign exchange rate risk, and there is still quite a bit of uncertainty surrounding U.S. trade policy. But this is a massive valuation gap, and it could still be a good time to buy. To be clear, I think all three of these ETFs are attractive right now, and I own shares of all three in my own portfolio. But I bought them because I think they'll perform very well over the next few years -- not the next few weeks or months. Keep that in mind when considering if they're right for your goals. Before you buy stock in Vanguard Real Estate ETF, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Vanguard Real Estate ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Matt Frankel has positions in Vanguard International High Dividend Yield ETF and Vanguard Real Estate ETF. The Motley Fool has positions in and recommends Vanguard Real Estate ETF and Vanguard Whitehall Funds-Vanguard High Dividend Yield ETF. The Motley Fool recommends Nestlé. The Motley Fool has a disclosure policy. All-Time Highs for Stocks: These 2 ETFs Still Look Undervalued was originally published by The Motley Fool
